Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nausea 5Vomiting 4Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Weight Loss 1Radiation Injuries 1Neoplasms, Germ Cell and Embryonal 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1Anorexia Nervosa with Significantly Low Body Weight 1Anorexia 1

Interventions

Mirtazapine 4Megestrol Acetate 4nabiximols 1anamorelin 1Watchful Waiting 1Thalidomide 1Olanzapine 1Observation 1Megestrol 1Infliximab 1Gemcitabine 1Flurandrenolone 1EOM613 1Dronabinol 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anorexia × Olanzapine × Clear all
NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
66 enrolled
Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡